Publication
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial
Paul Moayyedi, John W. Eikelboom, Jackie Bosch, Stuart J. Connolly, Leanne Dyal, Olga Shestakovska, Darryl Leong, Sonia S. Anand, Stefan Störk, Kelly R.H. Branch, Deepak L. Bhatt, Peter B. Verhamme, Martin O’Donnell, Aldo P. Maggioni, Eva M. Lonn, Leopoldo S. Piegas, Georg Ertl, Matyas Keltai, Nancy Cook Bruns, Eva Muehlhofer, Gilles R. Dagenais, Jae-Hyung Kim, Masatsugu Hori, P. Gabriel Steg, Robert G. Hart, Rafael Diaz, Marco Alings, Petr Widimsky, Alvaro Avezum, Jeffrey Probstfield, Jun Zhu, Yan Liang, Patricio Lopez-Jaramillo, Ajay Kakkar, Alexander N. Parkhomenko, Lars Ryden, Nana Pogosova, Antonio Dans, Fernando Lanas, Patrick J. Commerford, Christian Torp-Pedersen, Tomek Guzik, Dragos Vinereanu, Andrew M. Tonkin, Basil S. Lewis, Camilo Felix, Khalid Yusoff, Kaj Metsarinne, Keith A.A. Fox, Salim Yusuf
Gastroenterology, August 2019, Elsevier
DOI: 10.1053/j.gastro.2019.04.041